Market Summary
USD8.85-0.19
Market Closed-2.10%
NRIX Stock Price
NRIX RSI Chart
NRIX Valuation
NRIX Price/Sales (Trailing)
NRIX Profitability
NRIX Fundamentals
NRIX Revenue
NRIX Earnings
Price Action
52 Week Range
8.2215.09
(Low)(High)
Last 7 days
-0.1%
Last 30 days
3.3%
Last 90 days
-11.6%
Trailing 12 Months
-30.9%
NRIX Financial Health
NRIX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for NRIX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-07-31 | van Houte Hans | sold | -12,020 | 9.6547 | -1,245 | chief financial officer |
2023-07-31 | Ring Christine | sold | -13,709 | 9.6547 | -1,420 | general counsel |
2023-07-31 | Hansen Gwenn | sold | -18,189 | 9.6547 | -1,884 | chief scientific officer |
2023-07-30 | Hansen Gwenn | acquired | - | - | 5,207 | chief scientific officer |
2023-07-30 | Ring Christine | acquired | - | - | 3,924 | general counsel |
2023-07-30 | van Houte Hans | acquired | - | - | 4,886 | chief financial officer |
2023-05-01 | Wolff Stefani | sold | -3,377 | 9.8763 | -342 | evp and coo |
2023-05-01 | Ring Christine | sold | -6,735 | 9.8763 | -682 | general counsel |
2023-05-01 | Hansen Gwenn | sold | -11,219 | 9.8763 | -1,136 | chief scientific officer |
2023-05-01 | van Houte Hans | sold | -7,120 | 9.8763 | -721 | chief financial officer |
Which funds bought or sold NRIX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | reduced | -4.37 | 48,000 | 690,000 | -% |
2023-09-06 | Deep Track Capital, LP | unchanged | - | 3,327,590 | 29,948,300 | 1.39% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 5.68 | 81,062 | 510,099 | -% |
2023-08-21 | Affinity Asset Advisors, LLC | reduced | -33.33 | -333,000 | 999,000 | 0.35% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -0.38 | 717,496 | 6,667,500 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | reduced | -40.33 | -1,578,250 | 3,223,250 | -% |
2023-08-15 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | reduced | -6.00 | 47,000 | 859,000 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 19.69 | 102,872 | 399,730 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 200 | 61,000 | 86,000 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 234 | 891,041 | 1,213,380 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Nurix Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 24, 2023 | deep track capital, lp | 5.75% | 2,717,171 | SC 13G | |
| Feb 14, 2023 | third rock ventures iii, l.p. | 0% | 0 | SC 13G/A | |
| Feb 14, 2023 | deep track capital, lp | 4.81% | 2,266,569 | SC 13G/A | |
| Feb 14, 2023 | price t rowe associates inc /md/ | 6.9% | 3,253,736 | SC 13G/A | |
| Feb 14, 2023 | redmile group, llc | 9.9% | 4,899,772 | SC 13G/A | |
| Feb 14, 2023 | baker bros. advisors lp | 9.99% | 4,801,954 | SC 13G/A | |
| Feb 08, 2023 | wasatch advisors inc | - | 0 | SC 13G | |
| Jan 25, 2023 | blackrock inc. | 8.8% | 4,142,528 | SC 13G/A | |
| Jun 10, 2022 | deep track capital, lp | 5.19% | 2,436,164 | SC 13G | |
| Feb 14, 2022 | third rock ventures iii, l.p. | 5.4% | 2,422,549 | SC 13G/A |
Recent SEC filings of Nurix Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 07, 2023 | 8-K | Current Report | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Aug 01, 2023 | 4 | Insider Trading | |
| Jul 13, 2023 | 8-K | Current Report | |
| Jul 13, 2023 | 10-Q | Quarterly Report |
Peers (Alternatives to Nurix Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AAPL | 2.7T | 383.9B | -3.49% | 14.63% | 28.86 | 7.12 | -0.93% | -4.89% |
MSFT | 2.4T | 211.9B | -3.06% | 31.92% | 32.56 | 11.12 | 6.88% | -0.52% |
GOOG | 1.7T | 289.5B | -1.47% | 30.51% | 27.19 | 5.72 | 4.10% | -15.36% |
AMZN | 1.3T | 538.0B | -4.72% | 10.07% | 101.87 | 2.47 | 10.73% | 12.62% |
| MID-CAP | ||||||||
JBLU | 1.5B | 9.9B | -28.14% | -36.34% | 55.75 | 0.15 | 24.14% | 106.11% |
NYMT | 795.7M | 246.5M | -4.07% | -6.47% | -5.01 | 3.23 | 6.65% | -174.04% |
| SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -14.29% | -1.08 | 2.51 | -0.20% | -204.67% |
PLAY | 1.5B | 2.2B | -10.06% | 7.70% | 11.01 | 0.71 | 38.20% | -10.10% |
MFA | 1.0B | 543.3M | -3.23% | 5.22% | -715.94 | 1.91 | 31.74% | 78.13% |
NKLA | 961.6M | 56.2M | -5.30% | -69.36% | -1.14 | 17.12 | 40.31% | -12.26% |
BYND | 614.9M | 356.8M | -16.65% | -37.31% | -2.19 | 1.72 | -23.03% | 15.53% |
GPRO | 507.0M | 1.0B | -15.90% | -35.94% | -19.18 | 0.49 | -11.34% | -107.10% |
CGC | 462.3M | 453.3M | 100.98% | -69.12% | -0.38 | 1.02 | -16.04% | 55.90% |
INO | 104.1M | 13.7M | -12.49% | -77.75% | -0.62 | 7.62 | 413.65% | 52.51% |
Nurix Therapeutics News
Returns for NRIX
Cumulative Returns on NRIX
-33.9%
3-Year Cumulative Returns
Risks for NRIX
What is the probability of a big loss on NRIX?
94.0%
Probability that Nurix Therapeutics stock will be more than 20% underwater in next one year
91.0%
Probability that Nurix Therapeutics stock will be more than 30% underwater in next one year.
75.3%
Probability that Nurix Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does NRIX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Nurix Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Nurix Therapeutics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
| Revenue | 46.2% | 60,935,000 | 41,691,000 | 38,627,000 | 39,240,000 | 38,701,000 | 34,360,000 | 29,750,000 | 29,043,000 | 22,876,000 | 19,967,000 | 17,820,000 | 12,993,000 | 19,488,000 | 24,745,000 | 31,115,000 | 39,004,000 | 37,346,000 | 36,936,000 |
| Operating Expenses | 0.1% | 226,060,000 | 225,766,000 | 222,494,000 | 212,370,000 | 194,110,000 | 170,468,000 | 147,636,000 | 128,984,000 | 113,012,000 | 96,919,000 | 82,803,000 | 71,532,000 | 61,447,000 | 58,713,333 | 53,351,000 | 52,768,000 | - | - |
| S&GA Expenses | 5.2% | 40,614,000 | 38,590,000 | 37,997,000 | 37,448,000 | 36,043,000 | 33,900,000 | 31,202,000 | 28,636,000 | 24,631,000 | 20,390,000 | 16,309,000 | 12,660,000 | 10,506,000 | 9,648,000 | 8,326,000 | 8,736,000 | - | - |
| R&D Expenses | -0.9% | 185,446,000 | 187,176,000 | 184,497,000 | 174,922,000 | 158,067,000 | 136,568,000 | 116,434,000 | 100,348,000 | 88,381,000 | 76,529,000 | 66,494,000 | 58,872,000 | 50,941,000 | 49,065,333 | 45,025,000 | 44,032,000 | - | - |
| EBITDA | - | - | - | -175,011,000 | -166,734,000 | -150,793,000 | -132,335,000 | -114,273,000 | -96,655,000 | -86,314,000 | -73,178,000 | -61,597,000 | -55,073,000 | -38,973,000 | -35,288,000 | -19,106,000 | -7,268,000 | - | - |
| EBITDA Margin | - | - | - | -4.53 | -4.25 | -3.90 | -3.85 | -3.84 | -3.33 | -3.77 | -3.66 | -3.46 | -4.24 | -2.00 | -1.43 | -0.61 | -0.19 | - | - |
| Earnings Before Taxes | - | - | - | -180,360,000 | -171,301,000 | -154,550,000 | -135,392,000 | -117,063,000 | -99,278,000 | -88,837,000 | -75,601,000 | -63,777,000 | -57,213,000 | -41,113,000 | -37,474,666 | -21,460,000 | -9,668,000 | - | - |
| EBT Margin | - | - | - | -4.67 | -4.37 | -3.99 | -3.94 | -3.93 | -3.42 | -3.88 | -3.79 | -3.58 | -4.40 | -2.11 | -1.51 | -0.69 | -0.25 | - | - |
| Net Income | 11.8% | -157,436,000 | -178,560,000 | -180,360,000 | -171,345,000 | -154,471,000 | -135,452,000 | -117,194,000 | -99,406,000 | -89,088,000 | -55,126,000 | -43,242,000 | -36,847,000 | -20,757,000 | -31,405,000 | -21,699,000 | -10,906,666 | -11,506,000 | -10,740,000 |
| Net Income Margin | 100.0% | - | -4.28 | -4.67 | -4.37 | -3.99 | -3.94 | -3.94 | -3.42 | -3.89 | -2.76 | -2.43 | -2.84 | -1.07 | -1.27 | -0.70 | -0.28 | -0.31 | -0.29 |
| Free Cashflow | 100.0% | - | -176,678,000 | -172,051,000 | -163,304,000 | -145,450,000 | -143,373,000 | -90,061,000 | -79,641,000 | -55,615,000 | -38,031,000 | -4,633,000 | 3,054,000 | 14,486,667 | 53,814,000 | -1,050,000 | 16,868,000 | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
| Assets | -5.3% | 351 | 370 | 417 | 459 | 394 | 438 | 477 | 493 | 518 | 397 | 396 | 412 | 44.00 |
| Current Assets | 0.6% | 290 | 288 | 318 | 355 | 307 | 280 | 311 | 358 | 396 | 311 | 298 | 364 | 39.00 |
| Cash Equivalents | 75.6% | 59.00 | 34.00 | 64.00 | 48.00 | 42.00 | 79.00 | 81.00 | 147 | 188 | 126 | 119 | 266 | 35.00 |
| Net PPE | 4.4% | 18.00 | 18.00 | 17.00 | 17.00 | 16.00 | 14.00 | 11.00 | 10.00 | 8.00 | 7.00 | 7.00 | 7.00 | 4.00 |
| Liabilities | -5.6% | 91.00 | 96.00 | 113 | 117 | 128 | 132 | 134 | 118 | 120 | 127 | 106 | 104 | 54.00 |
| Current Liabilities | 11.4% | 72.00 | 65.00 | 71.00 | 68.00 | 73.00 | 66.00 | 66.00 | 51.00 | 47.00 | 48.00 | 45.00 | 41.00 | 16.00 |
| Shareholder's Equity | -5.2% | 260 | 274 | 304 | 343 | 267 | 306 | 342 | 375 | 398 | 270 | 290 | 308 | - |
| Retained Earnings | -5.5% | -466 | -441 | -401 | -354 | -308 | -263 | -220 | -183 | -154 | -127 | -103 | -83.78 | -60.46 |
| Additional Paid-In Capital | 1.2% | 728 | 719 | 709 | 701 | 579 | 571 | 564 | 558 | 552 | 398 | 394 | 391 | 3.00 |
| Shares Outstanding | 0.4% | 48.00 | 47.00 | 47.00 | 47.00 | 45.00 | 45.00 | 45.00 | 44.00 | 44.00 | 39.00 | 39.00 | 8.00 | 3.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
| Cashflow From Operations | 8.7% | -151 | -165 | -159 | -152 | -136 | -135 | -84.36 | -73.94 | -50.10 | -33.00 | -0.08 | 8.00 | 18.00 | 56.00 | 1.00 | 18.00 |
| Share Based Compensation | 6.4% | 32.00 | 31.00 | 28.00 | 25.00 | 22.00 | 19.00 | 16.00 | 13.00 | 10.00 | 7.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 0.00 |
| Cashflow From Investing | 1502.2% | 52.00 | 3.00 | 27.00 | -64.33 | -13.49 | -65.83 | -108 | -196 | -292 | -237 | -254 | -134 | -34.83 | -47.58 | 8.00 | 17.00 |
| Cashflow From Financing | -0.3% | 117 | 117 | 117 | 118 | 4.00 | 154 | 154 | 152 | 371 | 340 | 339 | 340 | 160 | 0.00 | 0.00 | 0.00 |
NRIX Income Statement
2023-05-31Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
May 31, 2023 | May 31, 2022 | May 31, 2023 | May 31, 2022 | |
| Total revenue | $ 30,676 | $ 11,432 | $ 43,361 | $ 21,053 |
| Operating expenses: | ||||
| Research and development | 45,763 | 47,493 | 91,579 | 90,630 |
| General and administrative | 11,678 | 9,654 | 21,499 | 18,882 |
| Total operating expenses | 57,441 | 57,147 | 113,078 | 109,512 |
| Loss from operations | (26,765) | (45,715) | (69,717) | (88,459) |
| Interest and other income, net | 2,488 | 314 | 4,707 | 525 |
| Net loss | $ (24,277) | $ (45,401) | $ (65,010) | $ (87,934) |
| Net loss per share, basic (in USD per share) | $ (0.45) | $ (1.01) | $ (1.20) | $ (1.96) |
| Net loss per share, diluted (in USD per share) | $ (0.45) | $ (1.01) | $ (1.20) | $ (1.96) |
| Weighted-average number of shares outstanding, basic (in shares) | 54,259,045 | 44,898,409 | 54,144,909 | 44,797,235 |
| Weighted-average number of shares outstanding, diluted (in shares) | 54,259,045 | 44,898,409 | 54,144,909 | 44,797,235 |
| Collaboration revenue | ||||
| Total revenue | $ 10,676 | $ 11,432 | $ 23,361 | $ 21,053 |
| License revenue | ||||
| Total revenue | $ 20,000 | $ 0 | $ 20,000 | $ 0 |
NRIX Balance Sheet
2023-05-31Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | May 31, 2023 | Nov. 30, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 58,958 | $ 64,474 |
| Marketable securities, current | 222,219 | 244,667 |
| Prepaid expenses and other current assets | 8,837 | 9,308 |
| Total current assets | 290,014 | 318,449 |
| Marketable securities, non‑current | 27,463 | 63,879 |
| Operating lease right-of-use assets | 9,941 | 12,345 |
| Property and equipment, net | 18,495 | 17,163 |
| Restricted cash | 901 | 901 |
| Other assets | 3,810 | 4,022 |
| Total assets | 350,624 | 416,759 |
| Current liabilities: | ||
| Accounts payable | 4,525 | 5,064 |
| Accrued expenses and other current liabilities | 18,091 | 22,428 |
| Operating lease liabilities, current | 5,583 | 5,530 |
| Deferred revenue, current | 44,063 | 37,633 |
| Total current liabilities | 72,262 | 70,655 |
| Operating lease liabilities, net of current portion | 3,758 | 6,434 |
| Deferred revenue, net of current portion | 14,683 | 35,974 |
| Total liabilities | 90,703 | 113,063 |
| Commitments and contingencies (Note 6) | ||
| Stockholdersʼ equity: | ||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2023 and November 30, 2022; no shares issued and outstanding as of May 31, 2023 and November 30, 2022 | 0 | 0 |
| Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2023 and November 30, 2022; 47,631,208 and 47,172,299 shares issued and outstanding as of May 31, 2023 and November 30, 2022, respectively | 48 | 47 |
| Additional paid-in capital | 728,038 | 709,220 |
| Accumulated other comprehensive loss | (1,903) | (4,319) |
| Accumulated deficit | (466,262) | (401,252) |
| Total stockholdersʼ equity | 259,921 | 303,696 |
| Total liabilities and stockholdersʼ equity | $ 350,624 | $ 416,759 |
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.